TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/17/2025
Back to search
Official data from USPTO
ASTARTZ
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079342589Class
1, 5, 40, 42, 45
Filing
79342589
Registration
7141339
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
10/22/2025
Trademark type
Combined
Nice classes
1, 5, 40, 42, 45
Filing date
02/25/2022
Registration date
08/22/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/22/2023
Last transaction
10/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
Tokyo 136-0075, JP
Examiner
EISNACH,MICHAEL PATRICK
Law office
L40
Current location
TMEG LAW OFFICE 104
Mark description
The mark consists of the Greek letter "alpha" before the term "STARTZ" appearing as one word in stylized format.
Holders and representatives
Holders
NIHON MEDI-PHYSICS CO., LTD.
Representatives
Marina Dostal GE Precision Healthcare LLC
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Industrial chemicals; chemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of radiopharmaceuticals; radioactive elements for scientific purposes; isotopes for industrial purposes; peptide substrates for scientific purposes; peptide for use in the manufacture of pharmaceuticals; chelating agents for use in the manufacture of pharmaceuticals; polypeptides for scientific purposes; antibodies for scientific purposesother than for medical or veterinary use; chelate compound; organic chelating agents; metal chelating agents
Class 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the diagnosis of cancer; chemical reagents for medical purposes; medical diagnostic reagents; radioactive substances for medical purposes; isotopes for medical purposes; radioisotope markers for therapeutic or diagnostic use; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; synthetic peptides for pharmaceutical purposes for the treatment of cancer; synthetic peptides for pharmaceutical purposes for the diagnosis of cancer; pharmaceuticals consisting of antibodies for the treatment of cancer; pharmaceuticals consisting of antibodies for the diagnosis of cancer; pharmaceuticals consisting of antibody fragments for the treatment of cancer; pharmaceuticals consisting of antibody fragments for the diagnosis of cancer; pharmaceuticals consisting of antibody derivatives for the treatment of cancer; pharmaceuticals consisting of antibody derivatives for the diagnosis of cancer; antibodies for medical purposes
Class 40
Custom manufacture of pharmaceuticals; custom manufacture of investigational new drug; custom manufacture of radiopharmaceuticals; custom synthesis of labeled compound; custom manufacture of peptides; custom manufacture of antibodies; custom manufacture of proteins; custom protein modification; custom antibody modification; custom extraction of pharmaceuticals and veterinary preparations; custom synthesis and refining of pharmaceuticals and veterinary preparations; custom peptide synthesis services; custom synthesis and refining of pharmaceuticals consisting of antibodies; custom manufacture of pharmaceuticals consisting of antibodies; custom synthesis and refining of pharmaceuticals consisting of antibody fragments; custom manufacture of pharmaceuticals consisting of antibody fragments; custom synthesis and refining of pharmaceuticals consisting of antibody derivatives; custom manufacture of pharmaceuticals consisting of antibody derivatives; custom radioactive labeling of antibodies; custom radioactive labeling of antibody fragments; custom radioactive labeling of antibody derivatives; custom radioactive labeling of peptides
Class 42
Research and development of medicines; testinginspection or research services in the fields of pharmaceuticals; advisoryconsultancy and providing information relating to testinginspection or research services in the fields of pharmaceuticals; development of pharmaceuticals; advisoryconsultancy and providing information relating to development of pharmaceuticals; conducting clinical trials for pharmaceuticals for others; advisoryconsultancy and providing information relating to clinical trials for pharmaceuticals; research and development of radiopharmaceuticals; development of radiopharmaceuticals; advisoryconsultancy and providing information relating to development of radiopharmaceuticals; research and development services relating to peptides; research and development services in the field of antibodies; research and development services relating to peptide labeling by radioactive substances; research and development services relating to antibody labeling by radioactive substances
Class 45
Granting of licenses to others for the use of intellectual property; legal servicesexploitation of industrial property rights
Publications
History of USPTO decisions and trademark events.
46 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/17/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/17/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/17/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/17/2025
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
06/18/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
05/10/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/09/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/19/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/27/2023
FIMP
FINAL DISPOSITION PROCESSED
11/27/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/22/2023
ES7R
TEAS SECTION 7 REQUEST RECEIVED
08/28/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/22/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/22/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/06/2023
CHPB
POST PUBLICATION AMENDMENT - ENTERED
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/06/2023
PUBO
PUBLISHED FOR OPPOSITION
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/17/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/17/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/17/2023
APET
ASSIGNED TO PETITION STAFF
05/15/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
05/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
05/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/01/2023
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/26/2023
PBMR
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
04/25/2023
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
04/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/19/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/18/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/17/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/17/2023
RFNT
REFUSAL PROCESSED BY IB
03/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/15/2023
RFRR
REFUSAL PROCESSED BY MPU
02/15/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/20/2022
CNRT
NON-FINAL ACTION WRITTEN
12/19/2022
DOCK
ASSIGNED TO EXAMINER
12/09/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/30/2022
MAFR
APPLICATION FILING RECEIPT MAILED
06/28/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/23/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
06/22/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/16/2022
Continuous trademark protection
Get notified about every new filing that threatens ASTARTZ or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.